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ABSTRACT 
Background: Biodegradable polymers for release of antiproliferative drugs from metallic drug-eluting 
stents (DES) aim to improve long-term vascular healing and efficacy. We designed a large scale 
clinical trial to compare a novel thin strut, cobalt chromium DES with silicon carbide coating releasing 
sirolimus from a biodegradable polymer (Orsiro, O-SES) with the durable polymer-based Xience 
Prime everolimus-eluting stent (X-EES) in an all-comers patient population. 
Design: The multicenter BIOSCIENCE trial (NCT01443104) randomly assigned 2,119 patients to 
treatment with biodegradable polymer SES or durable polymer EES at 9 sites in Switzerland. Patients 
with chronic stable coronary artery disease or acute coronary syndromes, including non-ST-elevation 
and ST-elevation myocardial infarction, were eligible for the trial if they had at least one lesion with a 
diameter stenosis >50% appropriate for coronary stent implantation. The primary endpoint target 
lesion failure (TLF) is a composite of cardiac death, target-vessel myocardial infarction, and clinically-
driven target lesion revascularization within 12 months. Assuming a TLF rate of 8% at 12 months in 
both treatment arms and accepting 3.5% as a margin for non-inferiority, inclusion of 2,060 patients 
would provide 80% power to detect non-inferiority of the biodegradable polymer SES compared with 
the durable polymer EES at a one-sided type I error of 0.05. Clinical follow-up will be continued 
through five years.  
Conclusion: The BIOSCIENCE trial will determine whether the biodegradable polymer SES is non-
inferior to the durable polymer EES with respect to TLF.  
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BACKGROUND 
Early generation drug-eluting stents (DES) have significantly reduced neointimal hyperplasia and the 
need for repeat revascularizations compared with bare metal stents (1). The reduction in restenosis 
came at the expense of an increased risk of very late stent thrombosis (2), motivating the 
development of newer generation devices. DES typically consist of three components: a metal 
scaffold, an antiproliferative agent, and a polymer matrix controlling the release of the drug. 
Modifications and technical refinements of each of the three components have contributed to an 
improvement in safety and efficacy of DES in recent years. New generation DES with thin strut stent 
platforms, biocompatible polymers and lower dosages of limus-analogues largely eliminated the risk 
of very late stent thrombosis while maintaining the antirestenotic efficacy of early generation DES (3, 
4). 
The polymer matrix of early generation DES has been shown to elicit an inflammatory response. 
Histopathological analysis of very late stent thrombosis specimens showed evidence of localized 
hypersensitivity reactions with eosinophilic infiltrates and aggregates of giant cells around polymer 
fragments (5). A prolonged inflammatory response to the polymer has hence been associated with 
delayed vascular healing with impaired stent strut endothelialization (6) and pathologic vessel 
remodeling resulting in coronary evaginations with secondary incomplete stent apposition (7). 
Moreover, early generation DES have been associated with endothelial dysfunction (8) and an 
increased risk of neoatherosclerosis (9) compared with bare metal stents. Delayed vascular healing 
after implantation of early generation DES may not only be the underlying mechanism of very late 
stent thrombosis, but also explain the catch-up phenomenon of delayed late loss observed during 
long-term angiographic follow after DES implantation (10).  
DES with biodegradable polymers have been designed to reduce the inflammatory stimulus and 
enhance vascular healing during long-term follow-up. Several randomized controlled trials have 
compared DES with biodegradable polymers with early and new generation DES. In a pooled analysis 
of three trials comparing DES with biodegradable polymers with early generation SES, biodegradable 
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polymer DES have been shown to reduce the risk of target lesion revascularization and stent 
thrombosis throughout four years of follow-up (11). In the COMPARE II trial, biodegradable polymer 
biolimus-eluting stents proved non-inferior in direct comparison with durable polymer EES with 
respect to a composite of cardiac death, myocardial infarction and clinically-indicated target vessel 
revascularization at one year (12). Similarly, the NEXT trial demonstrated no significant differences 
between biolimus-eluting stents with a biodegradable polymer and EES with a durable polymer with 
regard to the primary efficacy endpoint target lesion revascularization at one year (13). Of note, all 
biodegradable polymer stents used in the trials mentioned above were based on stainless steel 
platforms with a strut thickness comparable to early generation DES and have not been combined 
with newer generation metallic platforms.           
A series of randomized clinical trials comparing EES with early generation DES and zotarolimus-
eluting stents established EES as the current standard of care in terms of safety and efficacy (14). The 
biodegradable polymer SES (Orsiro, Biotronik, Bülach, Switzerland) combines a biodegradable poly-L 
lactic (PLLA) polymer with an ultrathin strut (60 μm) cobalt-chromium L605 platform covered with an 
amorphous silicon-carbide layer. The SES with biodegradable polymer has been compared with 
durable polymer EES in a randomized controlled trial with angiographic follow-up and was shown to 
be non-inferior in terms of the primary endpoint in-stent late lumen loss at nine months (0.10 ± 0.31 
mm vs. 0.11 ± 0.29 mm, pnoninferiority <0.0001). Findings from optical coherence tomography and 
intravascular ultrasound showed adequate stent strut coverage in both groups and documented a 
smaller neointimal area in patients allocated to SES with a biodegradable polymer, respectively (15). 
We therefore designed a randomized controlled, non-inferiority trial comparing the biodegradable 
polymer SES with the durable polymer EES in an all-comers population with the primary clinical 
endpoint target-lesion failure (TLF). 
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TRIAL DESIGN 
Study Design and Primary Hypothesis 
The BIOSCIENCE trial is a randomized, assessor blind, multicenter, non-inferiority trial comparing SES 
with biodegradable polymer (Orisro, O-SES) with EES with durable polymer (Xience prime/xpedition, 
X-EES) in an unselected patient population. The study protocol was designed by the steering 
committee (TP, PJ, SW), and all data were managed by the Clinical Trials Unit Bern, Switzerland. The 
trial is powered to investigate the study hypothesis that SES with biodegradable polymer are non-
inferior to durable polymer EES stents with respect to target lesion failure (TLF), defined as a 
composite of cardiac death, target vessel myocardial infarction (MI), and clinically driven target 
lesion revascularization (TLR) within 12 months. 
 
Statistical Analysis 
The sample size calculation was based on event rates reported in the COMPARE trial (12), the 
RESOLUTE AC trial (16), and the LESSON registry (3), assuming a TLF rate of 8% at 12 months in both 
treatment arms. A non-inferiority margin of 3.5% was defined for non-inferiority of the O-SES 
compared with the X-EES. Enrolment of 2060 patients was calculated to provide 80% power to detect 
non-inferiority at a one-sided type I error of 0.05. Clinical endpoints will be analyzed according to the 
intention-to-treat principle. Lesion-level data will be analysed using linear and logistic mixed effects 
models to account for the non-independence of measurements from the same patient. 
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Study Population 
Patients eligible for PCI with at least one lesion of >50% diameter stenosis suitable for stent 
implantation qualified for enrolment. The inclusion and exclusion criteria are summarized in table 1. 
All patients provided written informed consent.  
Between March 2012 and May 2013, a total of 2,119 patients were randomly assigned to treatment 
with O-SES or X-EES at 9 centers in Switzerland. Random stent allocation was performed by means of 
an electronic web database “Cardiobase” (Copyright by Department of Cardiology, CTU Bern, 
Switzerland and 2mt software GmbH, Ulm, Germany) in a 1:1 ratio stratified according to center and 
presence or absence of ST –segment elevation myocardial infarction.  
 
Procedure 
PCI was performed according to current guidelines. Lesion preparation in terms of predilatation was 
left to the discretion of the operator. In case of multivessel disease, all lesions treated within the 
same or during a subsequent staged procedure had to be treated with the assigned study stent. 
There was no restriction with regards to type or number of lesions.  
 
Study Medications 
Unfractionated heparin at a dose of at least 5000 IE or 70-100 IE/kg body weight was administered 
during the procedure. Alternative treatment with bivalirudin and administration of GpIIb/IIIa 
inhibitors was left to the discretion of the operator.  
Patients were loaded with acetylsalicylic acid at a dosage of at least 250 mg prior to the procedure 
and with clopidogrel (recommended dosage of 600 mg), prasugrel (recommended dosage of 60 mg) 
or ticagrelor (recommended dosage of 180 mg) immediately following stent implantation. 
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Combination of dual antiplatelet therapy was left to the discretion of the participating center. Dual 
antiplatelet therapy was continued for at least 6 months according to local practice. 
 
Pre-specified Analyses 
We will perform stratified analyses of the primary endpoint across major subgroups using the 
Mantel-Cox method. Subgroup analyses of the primary endpoint will be performed with respect to 
acute coronary syndrome status, acute ST-segment elevation myocardial infarction (also used as 
stratification during randomization), off- versus on-label indication, and diabetes. Rates of 
cerebrovascular events and bleeding complications will be analysed according to type and duration 
of antithrombotic and antiplatelet strategy. 
 
Definitions 
Target lesion failure (TLF) is defined as the composite of cardiac death, target vessel myocardial 
infarction, and clinically driven target lesion revascularization. All definitions are outlined in detail in 
the appendix. The clinical endpoints will be adjudicated by an independent event adjudication 
committee.  
 
Data Collection 
Patient data are collected in a web-based data entry system hosted at the Clinical Trials Unit,  
University of Bern, Switzerland. Data entry is performed by the study personnel on site. Central and 
on-site data monitoring is organized by the Clinical Trials Unit according to a pre-specified monitoring 
plan. All electronic case report forms underwent central data monitoring. On-site monitoring was 
performed of the complete case report forms of first 10 patients included at each participating site, 
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followed by a random sample of 20% at each site. Written informed consent for participation in the 
study was verified in all study subjects.  All serious adverse events are submitted to the Clinical Trials 
Unit at the University of Bern, Switzerland, in a blinded fashion. Any death, myocardial infarction, 
revascularization procedure, stent thrombosis, cerebrovascular accident, and bleeding event will be 
independently adjudicated by a blinded clinical event committee. 
 
CONCLUSION 
The BIOSCIENCE trial is a randomized multicenter study enrolling a total of 2,119 patients, which will 
determine whether O-SES are non-inferior to X-EES in terms of the primary endpoint TLF at 12 
months.  
 
FUNDING 
The study is investigator-initiated and supported by an unrestricted grant from Biotronik, Bülach. 
Switzerland. The funding source was not involved in the design of the study or data collection and 
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APPENDIX 
Study Organisation 
Sponsor: Clinical Trials Unit Bern, Bern, Switzerland and Department of Cardiologiy, Bern University 
Hospital, Bern, Switzerland.  
Funding: Unrestricted grant from Biotronik, Bülach, Switzerland 
Steering committee: Thomas Pilgrim, Peter Jüni, Stephan Windecker 
Clinical adjudication committee: Pascal Vranckx, Hasselt, Belgium (Chair); Gerrit Hellige, Solothurn, 
Switzerland; Daniel Mattle, Münsterlingen, Switzerland. 
Data coordination and analysis: Clinical Trials Unit Bern, Bern University Hospital, Switzerland (Dik 
Heg, Sven Trelle, Peter Jüni). 
Site management and on-site data monitoring: Clinical Trials Unit Bern, Bern University Hospital, 
Bern, Switzerland (Brigitte Wanner, Lucia Kacina, Stefanie Hossmann). 
Central data monitoring: Clinical Trials Unit Bern, Bern University Hospital, Bern, Switzerland (Timon 
Spörri). 
Data safety and monitoring board: none 
SECONDARY ENDPOINTS 
Clinically indicated and not clinically indicated target lesion revascularization (TLR); clinically 
indicated and not clinically indicated target vessel revascularization (TVR); target vessel failure (TVF); 
cardiac death; all death (cardiac and non-cardiac); myocardial infarction; definite stent thrombosis; 
definite and probable stent thrombosis; device success defined as achievement of a final residual 
diameter stenosis of <30% (by visual estimation), using the assigned device only; lesion success 
defined as achievement of <30% residual stenosis (by visual estimation), using any PCI method; 
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procedural success defined as achievement of a final diameter stenosis of <30% (by visual 
estimation) using any PCI method, without the occurrence of death, MI, or repeat target vessel 
revascularization during hospital stay. 
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ENDPOINT DEFINITIONS 
1. Death 
All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. 
Cardiac death: Any death due to immediate cardiac cause (e.g. MI, low-output failure, fatal 
arrhythmia). Unwitnessed death and death of unknown cause will be classified as cardiac death. 
Vascular death: Death due to cerebrovascular disease, pulmonary embolism, ruptured aortic 
aneurysm, dissecting aneurysm, or other vascular cause.  
Non-cardiovascular death: Any death not covered by the above definitions, including death due to 
infection, sepsis, pulmonary causes, accident, suicide or trauma. 
2. Myocardial infarction 
Spontaneous MI is documented in case of a typical rise and gradual fall of biochemical markers in 
combination with either one of the following characteristics: ischemic symptoms, development of 
new pathologic (defined by Minnesota Code) Q-waves on the ECG, ECG changes indicative of 
ischemia (ST segment elevation or depression), pathologic findings of an acute MI, development of 
new pathologic Q-waves on follow-up ECG in the absence of cardiac biomarker assessment during 
the acute  event. 
According to the electrocardiographic definition we distinguish between Q-wave MI and Non Q-wave 
MI.  Q-wave MI is determined by the presence of new pathological Q’s in 2 or more contiguous leads 
(according to the Minnesota code as assessed by the ECG core laboratory) with or without post-
procedure CK or CK-MB levels elevated above normal. All other MIs are classified as Non Q-wave 
MI’s. 
MI’s occurring within 48 hours after PCI or within 7 days after CABG are categorized as peri-
procedural MI’s. In patients presenting with stable angina peri-procedural MI is defined as elevation 
of total CK >2 times the upper limit of normal (ULN) in the presence of a confirming cardiac specific 
biomarker obtained after the procedure. Alternatively, CKMB >3 times ULN and Troponin elevation 
>5 times the 99th percentile is considered as a periprocedural MI in the absence of total CK 
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measurement or CKMB measurement, respectively. MI following CABG is defined as development of 
new Q-waves not present on the patient's baseline ECG and a peak CKMB/peak total CK ratio >10% 
on 3 consecutive samples within 7 days post intervention, or CKMB >5x ULN. 
Peri-procedural MI in the setting of evolving MI is documented for recurrent chest pain lasting >20 
minutes (or new ECG changes consistent with MI) in combination with a >50% elevation of peak CK 
(or CKMB in the absence of CK) level above the previous level measured within 24 hours after the 
event. If the elevated CK (or CK-MB) levels from the index infarction are falling or have returned to 
normal within 24 hours post index PCI, a new elevation of CK >2 x ULN within 24 hours post index PCI 
if the CK level has returned to <ULN, or a rise by >50% above the previous nadir level if the CK level 
has not returned to <ULN are defined as periprocedural MI. 
3. Target-vessel myocardial infarction 
Target-vessel myocardial infarction is defined as any myocardial infarction that is not clearly 
attributable to a non-target-vessel. 
4. Target-vessel 
The target vessel is the index coronary artery which was in physical contact with any component 
(guiding catheter, guide wire, balloon catheter, etc.) of the angioplasty hardware during the initial 
procedure. 
5. Target lesion 
The target lesion is the treated lesion starting 5 mm proximal of the stented lesion and to end 5 mm 
distal of the stented lesion. 
6. Target lesion revascularization 
Target lesion revascularization (TLR) is defined as any repeat percutaneous intervention of the target 
lesion or bypass surgery of the target vessel. TLRs are documented as clinically-indicated if repeat 
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angiography shows a percent diameter stenosis ≥50% and the patients has a history of recurrent 
angina, objective signs of ischemia, or abnormal results of any invasive functional diagnostic tests. 
TLRs for percent diameter stenosis ≥70% are considered clinically significant even in the absence of 
the above-mentioned criteria.  
7. Device success 
Device success is defined as the attainment of <30% residual stenosis by QCA (or <20% by visual 
assessment), using the assigned device only.   
8. Lesion success 
Lesion success is define as the attainment of <30% residual stenosis by QCA (or <20% by visual 
assessment), using any percutaneous method.  
9. Procedural success 
Procedural success is defined as the attainment of <30% residual stenosis by QCA (or <20% by visual 
assessment) in all lesions using any percutaneous method , without the occurrence of death, MI, or 
repeat revascularization of the target vessel during the hospital stay.  
10. Stent thrombosis 
Stent thrombosis is categorized into definite, probable and possible according to the definition 
provided by the Academic Research Consortium (17).  
11. Bleeding 
Bleeding complications will be defined in accordance with the BARC criteria (18). 
 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
15 
 
REFERENCES 
1. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-
metal stents: a collaborative network meta-analysis. Lancet 2007; 370:937-48. 
2. Daemen J, Wenaweser P, Tsuchida K, ert al. Early and late coronary stent thrombosis of 
sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large 
two-institutional cohort study. Lancet 2007;369(9562):667-78. 
3. Räber L, Magro M, Stefanini GG , et al. Very late coronary stent thrombosis of a newer-
generation everolimus-eluting stent compared with early-generation drug-eluting stents: a 
prospective cohort study. Circulation. 2012;125(9):1110-21 
4.  Bangalore S, Kumar S, Fusaro M et al. Short- and long-term outcomes  with drug-eluting and 
bare-metal coronary stents: a mixed-treatment comparison analysis of 117762 patient-years 
of follow-up from randomized trials. Circulation 2012;125:2873-91. 
5. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis 
secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004;109(6):701-5. 
6. Barlis P, Regar E, Serruys PW, et al.  An optical coherence tomography study of a 
biodegradable vs. durable polymer-coated limus-eluting stent: a LEADERS trial sub-study. Eur 
Heart J 2010;31(2):165-76. 
7. Cook S, Ladich E, Nakazawa G, et al. Correlation of intravascular ultrasound findings with 
histopathological analysis of thrombus aspirates in patients with very late drug-eluting stent 
thrombosis. Circulation 2009;120(5):391-9. 
8. Togni M, Windecker S, Cocchia R, et al. Sirolimus-eluting stents associated with paradoxic 
coronary vasoconstriction. J Am Coll Cardiol. 2005;46(2):231-6. 
9. Nakazawa G, Otsuka F, Nakano M, et al. The pathology of neoatherosclerosis in human 
coronary implants bare-metal and drug-eluting stents. J Am Coll Cardiol. 2011;57(11):1314-
22. 
 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
16 
 
10. Räber L, Wohlwend L, Wigger M, et al. Five-year clinical and angiographic outcomes of a 
randomized comparison of sirolimus-eluting and paclitaxel-eluting stents: results of the 
Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization LATE trial. 
Circulation. 2011 Jun 21;123(24):2819-28, 6 p following 2828. 
11. Windecker S. BioFLOW-II trial: Safety and Clinical Performance of the Drug- Eluting Orsiro 
Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II. Presented 
at EuroPCR 2013. May 25th, 2013. Paris, France. 
12. Smits PC, Hofma S, Togni M et al. Abluminal biodegradable polymer biolimus-eluting stent 
versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, 
non-inferiority trial. Lancet 2013;381:651-60. 
13. Natsuaki M, Kozuma K, Morimoto T et al. Biodegradable polymer biolimus-eluting stent 
versus durable polymer everolimus-eluting stent: a randomized, controlled, non-inferiority 
trial. J Am Coll Cardiol 2013;62:181-90.  
14. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Stent thrombosis with drug-eluting and bare-
metal stents: evidence from a comprehensive network meta-analysis. Lancet. 
2012;379(9824):1393-402.  
15. Windecker S. BioFLOW-II trial: Safety and Clinical Performance of the Drug- Eluting Orsiro 
Stent in the Treatment of Subjects With Single De Novo Coronary Artery Lesions-II. Presented 
at EuroPCR 2013. May 25th, 2013. Paris, France.  
16. Serruys PW, Silber S, Garg S, et al. Comparison of zotarolimus-eluting and everolimus-eluting 
coronary stents. N Engl J Med. 2010;363(2):136-46.  
17. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: a case for 
standardized definitions. Circulation 2007;115(17):2344-51. 
18. Mehran R, Rao SV, Bhatt DL, et al. Standardized bleeding definitions for cardiovascular 
clinical trials: a consensus report from the Bleeding Academic Research Consortium. 
Circulation 2011;123(23):2736-47. 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
17 
 
 
Table 1 
Inclusion Criteria: 
1. Age ≥ 18 years; 
2. Symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, 
and acute coronary syndromes including NSTE-ACS and STE-ACS; 
3. Presence of one or more coronary artery stenosis >50% in a native coronary artery or a saphenous 
bypass graft in a vessel which can be treated with a stent ranging in diameter from 2.25 to 4.0 mm and 
can be covered with one or multiple stents;  
4. No limitation to the number of treated lesions, number of vessels or lesion length according to the 
randomization group. 
Exclusion Criteria: 
1. Pregnancy; 
2.   Known intolerance to aspirin, clopidogrel, heparin, stainless steel, sirolimus, everolimus, contrast 
material; 
3.   Inability to provide informed consent; 
4. Currently participating in another trial before reaching the primary endpoint; 
5. Planned surgery within 6 months of PCI unless dual antiplatelet therapy is maintained     
throughout the peri-surgical period. 
 
 
